Related Experiment Video
Updated: Apr 30, 2026
09:30
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
4.4K
Pharmaceutical approval update
Abstract:
Dapaglifozin (Farxiga) for improved glycemic control in type-2 diabetes, and trametinib (Mekinist) in combination with dabrafenib (Tafinlar) for the treatment of advanced, unresectable melanoma.
Insights
Dapagliflozin improves glycemic control in type-2 diabetes. Trametinib combined with dabrafenib treats advanced melanoma, offering new therapeutic options for these conditions.
Area of Science:
- Pharmacology and Therapeutics
- Oncology
- Endocrinology
Background:
- Type-2 diabetes mellitus (T2DM) poses a significant global health challenge, often requiring combination therapies for effective glycemic control.
- Advanced, unresectable melanoma remains a difficult-to-treat malignancy with limited therapeutic options.
Purpose of the Study:
- To evaluate the efficacy of dapagliflozin in improving glycemic control in patients with T2DM.
- To assess the effectiveness of the combination therapy of trametinib and dabrafenib in treating advanced, unresectable melanoma.
Main Methods:
- Clinical trials were conducted to assess dapagliflozin's impact on glycemic parameters.
- Patient cohorts received trametinib in combination with dabrafenib for melanoma treatment, with outcomes monitored.
Main Results:
- Dapagliflozin demonstrated significant improvements in glycemic control markers in T2DM patients.
- The combination of trametinib and dabrafenib showed promising response rates and improved progression-free survival in advanced melanoma.
Conclusions:
- Dapagliflozin is an effective agent for managing type-2 diabetes.
- Combination therapy with trametinib and dabrafenib represents a viable treatment strategy for advanced melanoma.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:26Drug Administration and Therapy Phases: Overview
1.9K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.9K
01:25Drug Regulation
3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K